Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4g
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Hypertriglyceridemia
Conditions
Hypertriglyceridemia, Cardiovascular Disease
Trial Timeline
Aug 1, 2011 โ Jun 1, 2012
NCT ID
NCT01408303About Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4g
Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4g is a phase 3 stage product being developed by AstraZeneca for Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01408303. Target conditions include Hypertriglyceridemia, Cardiovascular Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01408303 | Phase 3 | Completed |
Competing Products
20 competing products in Hypertriglyceridemia